Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Inhibitory effect of live-attenuated Listeria monocytogenes-based vaccines expressing MIA gene on malignant melanoma.

Qian Y, Zhang N, Jiang P, Chen S, Chu S, Hamze F, Wu Y, Luo Q, Feng A.

J Huazhong Univ Sci Technolog Med Sci. 2012 Aug;32(4):591-7. doi: 10.1007/s11596-012-1002-x. Epub 2012 Aug 11.


Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Wood LM, Paterson Y.

Front Cell Infect Microbiol. 2014 May 12;4:51. doi: 10.3389/fcimb.2014.00051. eCollection 2014. Review.


Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.

Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V.

Clin Vaccine Immunol. 2009 Jan;16(1):96-103. doi: 10.1128/CVI.00274-08. Epub 2008 Nov 19.


High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.

Kim SH, Castro F, Paterson Y, Gravekamp C.

Cancer Res. 2009 Jul 15;69(14):5860-6. doi: 10.1158/0008-5472.CAN-08-4855. Epub 2009 Jul 7.


A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA.

Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6.


Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.

Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X.

Int J Mol Med. 2012 Dec;30(6):1335-42. doi: 10.3892/ijmm.2012.1136. Epub 2012 Sep 20.


Development of a Listeria monocytogenes based vaccine against prostate cancer.

Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P.

Cancer Immunol Immunother. 2008 Sep;57(9):1301-13. doi: 10.1007/s00262-008-0463-z. Epub 2008 Feb 14.


Attenuated Listeria infection activates natural killer cell cytotoxicity to regress melanoma growth in vivo.

Shen H, Kanoh M, Maruyama S, Matsumoto A, Zhang W, Asano Y.

Microbiol Immunol. 2008 Feb;52(2):107-17. doi: 10.1111/j.1348-0421.2008.00018.x.


KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Skoberne M, Yewdall A, Bahjat KS, Godefroy E, Lauer P, Lemmens E, Liu W, Luckett W, Leong M, Dubensky TW, Brockstedt DG, Bhardwaj N.

J Clin Invest. 2008 Dec;118(12):3990-4001. doi: 10.1172/JCI31350. Epub 2008 Nov 6.


Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.

Prins RM, Bruhn KW, Craft N, Lin JW, Kim CH, Odesa SK, Miller JF, Liau LM.

Neurosurgery. 2006 Jan;58(1):169-78; discussion 169-78.


A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Sciaranghella G, Lakhashe SK, Ayash-Rashkovsky M, Mirshahidi S, Siddappa NB, Novembre FJ, Velu V, Amara RR, Zhou C, Li S, Li Z, Frankel FR, Ruprecht RM.

Vaccine. 2011 Jan 10;29(3):476-86. doi: 10.1016/j.vaccine.2010.10.072. Epub 2010 Nov 9.


Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.

Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A.

Cancer Gene Ther. 2011 Jan;18(1):53-62. doi: 10.1038/cgt.2010.48. Epub 2010 Aug 20.


Induction of protective immunity to Listeria monocytogenes in neonates.

Kollmann TR, Reikie B, Blimkie D, Way SS, Hajjar AM, Arispe K, Shaulov A, Wilson CB.

J Immunol. 2007 Mar 15;178(6):3695-701.


Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.

Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, Guha C.

Cancer Immunol Immunother. 2012 Dec;61(12):2227-38. doi: 10.1007/s00262-012-1257-x. Epub 2012 May 27.


Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13.


Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.

Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, Krakover J, Secord AA, Clay TM, Morse MA, Dubensky TW Jr, Brockstedt DG, Philip R, Giedlin M.

J Immunother. 2009 Oct;32(8):856-69. doi: 10.1097/CJI.0b013e3181b0b125.


Live-attenuated Listeria-based immunotherapy.

Rothman J, Paterson Y.

Expert Rev Vaccines. 2013 May;12(5):493-504. doi: 10.1586/erv.13.34. Review.


Attenuated Listeria monocytogenes, a Mycobacterium tuberculosis ESAT-6 antigen expression and delivery vector for inducing an immune response.

Yin Y, Tian D, Jia Y, Gao Y, Fu H, Niu Z, Sun L, Jiao X.

Res Microbiol. 2012 Sep-Oct;163(8):540-9. doi: 10.1016/j.resmic.2012.07.008. Epub 2012 Jul 23.


Supplemental Content

Support Center